Biotricity (BTCY) Q4 2026 earnings summary

Executive summary

• Revenue grew 16% year-over-year to $16.0 million, driven by technology fee income and expanded device sales, with gross profit margin improving to 81% from 76.6% the prior year.

• Net loss attributable to common stockholders narrowed significantly to $3.13 million from $11.94 million in the prior year, reflecting improved operating leverage and cost controls.

• The company continues to focus on commercialization of its Bioflux and Biocore cardiac monitoring solutions, expanding its sales footprint to 35 states and investing in AI-driven healthcare technologies.

• Management highlights a clear path to profitability, supported by recurring technology fee revenue and ongoing cost containment.

Financial highlights

• Revenue: $15.998 million for FY 2026, up from $13.790 million in FY 2025.

• Gross profit: $12.95 million (81% margin), up from $10.56 million (76.6% margin) year-over-year.

• Operating expenses decreased to $11.26 million from $13.01 million, mainly due to lower SG&A.

• Net loss before dividends: $2.40 million, a substantial improvement from $8.42 million loss in the prior year.

• Adjusted EBITDA for the quarter ended March 31, 2026 was $703,741, up 61% from the prior year quarter.

Outlook and guidance

• Management expects continued revenue growth and further improvement in gross margins as technology fees become a larger share of revenue.

• The company anticipates ongoing investment in R&D and commercialization, with a focus on expanding its product ecosystem and AI capabilities.

• Liquidity remains a concern, with additional capital raises likely needed to support growth and operations.